MedCity News January 25, 2026
When MRD testing evolves from a numerical readout into a definition of clonal behavior, it becomes what clinicians have needed all along: a tool that informs action, not just detection.
Two patients with acute myeloid leukemia (AML) achieve remission. Both test positive for measurable residual disease (MRD). Both show the same mutation at a similar variant allele frequency. By conventional metrics, they appear to carry the same risk. Six months later, one remains in remission. The other relapses. This divergence is not random. It reflects biology that current MRD tools are not equipped to measure.
The hidden assumption inside MRD
Most AML MRD testing approaches are built on an implicit assumption: residual cancer cells are interchangeable and that the presence...
Today's Sponsors
Today's Sponsor